Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

Summary

Participation Requirements

Description

This is a multicenter, randomized, double-blind, parallel-group controlled, Landiolol vs Placebo (saline), phase III trial assessing the efficacy and the safety of landiolol postoperative treatment on POAF occurrence within 7 days of surgery in patients undergoing cardiac surgery with sternotomy. Su...

This is a multicenter, randomized, double-blind, parallel-group controlled, Landiolol vs Placebo (saline), phase III trial assessing the efficacy and the safety of landiolol postoperative treatment on POAF occurrence within 7 days of surgery in patients undergoing cardiac surgery with sternotomy. Subjects are randomly assigned in a 1:1 ratio to receive either Landiolol or Placebo (saline). A stratification of the randomization is planned according to the hospital and the age of the patient (65 ? age ? 70 and age > 70). A preventive treatment is infused during at least the first 24 hours after surgery (in ICU) to each patient included in the study until the optimal oral betablocker dose. Continuous infusion of landiolol at 2 µg/kg/min (1.2 ml/h, for a 60 kg patient) in Landiolol group or continuous infusion of saline (at 1.2 ml/h for a 60 kg patient) in Placebo group is administrated until restoration of an effective oral beta-blocker treatment. Treatment: Treatment is initiated after the surgery, on arrival at the ICU (Day-0) in the absence of a contraindication. The target of continuous intravenous infusion of landiolol is 2 µg/kg/min (1.2 ml/h for a 60 kg patient), or placebo (saline) at the same infusion rate as landiolol. The modalities for initiating the treatment are as follows: No bolus is performed, Continuous infusion starting at the lowest dosage (1 µg/kg/min), Increasing in increments every 10 to 15 minutes until 2 µg/kg/min by maintaining a MAP ? 65 mmHg and HR ? 50/min. Relay with oral betablocker treatment: The relay with oral betablocker treatment, bisoprolol (1.25 mg x 2/day) for initial introduction (target HR < 100/min) or with the patient's preoperative beta-blocker in case of preoperative treatment, is resumed on Day-1 if possible or as soon as possible. The dosage of landiolol can be reduced as follows: Within the first hour after the first dose of the alternative medicinal product has been administered, the infusion rate of landiolol should be reduced by one-half (e.g. from 2 to 1 µg/kg/min). After administration of the second dose of the alternative medicinal product (12 hours later), the patient's response should be supervised and if satisfactory control is maintained for a least one hour, the landiolol infusion can be discontinued. Maximal duration of continuous intravenous treatment before oral betablocker relay is 5 days, exclusively administrated in ICU for safety reasons. Precautions for patient safety: The landiolol infusion should be decreased half and progressively re-increased every 15 min by step of 0.5 µg/kg/min and/or discontinued temporarily or permanently in case of: Bradycardia defined by HR < 50 /mim Hypotension defined by SAP < 90 mmHg or MAP < 65 mmHg Atrioventricular conduction treated by pacing Norepinephrine increase > 50% after introduction of landiolol infusion In case of POAF event: Patients will benefit from the usual care: Intravenous magnesium sulfate injection: 3 g over 1 hour Intravenous or per os treatment with amiodarone depending on patient's condition: Intravenous: IV bolus of 300 mg over 1 hour; then IV infusion pump of 150-600 mg per day Per os: loading dose with 4-6 tablets of 200 mg; then 2 tablets per day during one week If AF persists, cardioversion Anticoagulant therapy if required Treatment with landiolol or placebo is continued and the infusion rate is adjusted if needed as described above. Primary endpoint: Continuous monitoring of heart rate is performed in ICU and POAF event > 5 minutes and/or requiring medical treatment and/or cardioversion is recorded during the ICU stay and reported.

Tracking Information